全世界哪些治疗领域,药品热门、畅销?

2016-08-22 张智 赛柏蓝智库

2013-2015年,全球医药市场前十大治疗类别中,抗高血压药、精神疾药、抗菌药和止痛药的销售额有出现下滑,导致下滑的主要原因是部分类别的重磅炸弹品种专利到期。从各类别药物的发展趋势看,免疫系统药和糖尿病药从2013-2015年的增长速度在10%以上,其市场成长性较好,其次是抗肿瘤药、抗凝血药和皮肤药,增长速度超过5%。全球处方药市场十大畅销治疗类别历年的销售收入(单位:亿美元)数据来源于:IMS

2013-2015年,全球医药市场前十大治疗类别中,抗高血压药、精神疾药、抗菌药和止痛药的销售额有出现下滑,导致下滑的主要原因是部分类别的重磅炸弹品种专利到期。

从各类别药物的发展趋势看,免疫系统药和糖尿病药从2013-2015年的增长速度在10%以上,其市场成长性较好,其次是抗肿瘤药、抗凝血药和皮肤药,增长速度超过5%。

全球处方药市场十大畅销治疗类别历年的销售收入(单位:亿美元)

数据来源于:IMS

那些治疗领域的是研发的热点?

市场中在研药物根据来源不同,大致可分为化学合成小分子、生物制品和天然来源药物三类。毫无疑问,化学合成的小分子物质仍是候选药物的最主要来源。

目前,生物制品呈现出明显的增长态势,尤其是细胞治疗及基因治疗药物。分析1995年以来的研究数据可知,生物制品自20世纪90年代出现,在接下来的10年中,其在研发药品中的占比较为稳定。

自2010年以来,生物制品的发展得到了推动,但是增长较为缓慢。目前,生物制品在在研药品整体中的占比,已接近30%。但是,如果从过去20年的数据来看,在研生物制品药物的数量,几乎增长了近一倍。

从各治疗来看,抗肿瘤物、抗感染药物、神经系统药物、消化系统及代谢药物和心血管系统药物为排名Top5的在研药物的治疗领域分布情况。

其中,肿瘤药仍是药品研发的核心领域。其中免疫类抗肿瘤药物增长迅速,表明该类药物在抗肿瘤领域正逐渐受到重视。

全球新增在研药物的治疗领域分布状况

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006004, encodeId=575d200600413, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu Jun 08 03:30:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109857, encodeId=53e710985e4d, content=学习一下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Fri Sep 02 21:29:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108669, encodeId=7ca9108669d3, content=学习一下,有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 01 07:24:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107556, encodeId=e00e10e55631, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Aug 30 15:03:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102260, encodeId=6d5d10226027, content=总结的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Mon Aug 22 12:42:00 CST 2016, time=2016-08-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006004, encodeId=575d200600413, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu Jun 08 03:30:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109857, encodeId=53e710985e4d, content=学习一下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Fri Sep 02 21:29:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108669, encodeId=7ca9108669d3, content=学习一下,有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 01 07:24:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107556, encodeId=e00e10e55631, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Aug 30 15:03:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102260, encodeId=6d5d10226027, content=总结的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Mon Aug 22 12:42:00 CST 2016, time=2016-08-22, status=1, ipAttribution=)]
    2016-09-02 1771ae4158m

    学习一下,好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2006004, encodeId=575d200600413, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu Jun 08 03:30:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109857, encodeId=53e710985e4d, content=学习一下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Fri Sep 02 21:29:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108669, encodeId=7ca9108669d3, content=学习一下,有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 01 07:24:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107556, encodeId=e00e10e55631, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Aug 30 15:03:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102260, encodeId=6d5d10226027, content=总结的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Mon Aug 22 12:42:00 CST 2016, time=2016-08-22, status=1, ipAttribution=)]
    2016-09-01 1771ae4158m

    学习一下,有意思

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2006004, encodeId=575d200600413, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu Jun 08 03:30:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109857, encodeId=53e710985e4d, content=学习一下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Fri Sep 02 21:29:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108669, encodeId=7ca9108669d3, content=学习一下,有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 01 07:24:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107556, encodeId=e00e10e55631, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Aug 30 15:03:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102260, encodeId=6d5d10226027, content=总结的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Mon Aug 22 12:42:00 CST 2016, time=2016-08-22, status=1, ipAttribution=)]
    2016-08-30 李东泽

    很好,不错,以后会多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2006004, encodeId=575d200600413, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu Jun 08 03:30:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109857, encodeId=53e710985e4d, content=学习一下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Fri Sep 02 21:29:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108669, encodeId=7ca9108669d3, content=学习一下,有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 01 07:24:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107556, encodeId=e00e10e55631, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Aug 30 15:03:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102260, encodeId=6d5d10226027, content=总结的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Mon Aug 22 12:42:00 CST 2016, time=2016-08-22, status=1, ipAttribution=)]
    2016-08-22 半夏微凉

    总结的很好

    0

相关资讯

注意,这些药不能睡前服用!

1.降压药大部分人的血压在生物钟作用下,通常呈“双峰状”即“匙形状”,上午8~10点达高峰随后下降、下午2~6点又会上升,随后再次下降。故一般长效降压药在早上服,短效降压药每天三次给药的,第三次应在下午6点前给药。如果在睡前服用,睡后血药浓度到达峰值,血压大幅度下降,心、脑、肾等重要器官会出现供血不足。从而使血液中的血小板、纤维蛋白等凝血物质在血管内积聚成块,阻塞脑血管,极易引发缺血性脑中风。特拉

小道]重磅抢先!CFDA拟发布《关于进一步加强药品生产工艺监管的公告》

内容来自:不愿透露姓名网友 注:这只是草稿,,正式稿请以国家局最终发布的为准! 希望这次是国家局为药企给一个改正的机会,解决注册工艺与实际工艺不一致的老大难问题。作为药品生产企业,对于这种政策机会,绝对不能放过! 关于进一步加强药品生产工艺监管的公告 根据药品监督检查信息,部分药品生产企业存在不按照食品药品监管部门核准的生产工艺生产药品的问题。为进一步规范药品生产秩序,解决药品生产

我国将加强药品反垄断 遏制“商量涨”“任性涨”

继白酒、奶粉和汽车之后,我国的反垄断之剑将指向医药等百姓关心的领域。国家发展改革委价格监督检查与反垄断局副局长卢延纯在上海表示,下一步我国将加强药品反垄断,遏制药品价格“商量涨”“任性涨”等违反《反垄断法》的行为。 卢延纯是在近日上海举办的医药企业培训会上做上述表述的。他表示,医药产品事关人民群众生命健康,是反垄断部门关注的重点。我国药品长期实行政府定价,2015年刚刚放开。除了麻醉药品、精

来自毒品的药品有望上市:大麻二酚第二个罕见癫痫病显示疗效

GW Pharma宣布其大麻二酚(CBD)液体制剂Epidiolex在一个叫做Lennox-Gastaut症(LGS)的罕见儿童病的三期临床试验中显示积极疗效。在这个171人参与的试验中,Epidiolex降低44%每月癫痫发病。而安慰剂只降低22%。这些病人中值年龄15岁,平均使用三种抗癫痫药物。86%的患者使用Epidiolex出现不良反应,但安慰组也有69%的患者出现不良反应。另一个22

《药品注册管理办法》9年后最重大修改(附修订稿 VS 2007版)

7月25日,CFDA通过官网发布《药品注册管理办法(修订稿)》,向社会公开征求意见,时间为一个月。关于此修改稿的意见可于8月26日之前反馈给CFDA。时隔九年,与上一版2007年《药品注册管理办法》相比较,中国医药行业的情况发生了巨大的变化,药品注册管理工作的流程和范围需要进行与时俱进的重新调整:两万件药品注册申请积压待审,运动式的削峰药审无法真正改变这种积压的现状;药品僵尸文号盛行,如何从注

CFDA 2016年7月份总局批准31件药品上市

er-left-color: rgb(0, 0, 0); border-right-width: 1.2pt; border-right-style: solid; border-right-color: rgb(0, 0, 0); border-bottom-width: 1.2pt; border-bottom-style: solid; border-bottom-color: rgb(0,